Table 3

Association between autoantibody positivity and irAEs

Baseline positive for…Baseline negative for…P valueOR (95% CI)
Any irAE/any antibody25/37 (67.6%)37/106 (34.9%)<0.0013.89 (1.75 to 8.61)
Thyroiditis/anti-TPO and/or anti-Tg9/13 (69.2%)16/130 (12.3%)<0.00116.03 (4.42 to 58.17)
Arthralgia or arthritis/anti-CCP2 and/or RF1/10 (10.0%)4/133 (3.0%)0.2753.58 (0.360 to 35.50)
Dermatitis/antinuclear antibodies5/19 (26.3%)19/124 (15.3%)0.2391.97 (0.636 to 6.12)
Sicca symptoms/antinuclear antibodies2/19 (10.5%)17/124 (13.7%)0.7040.740 (0.157 to 3.50)
Colitis/antinuclear antibodies2/19 (10.5%)7/124 (5.60%)0.4221.97 (0.377 to 10.26)
  • In each cell, n/N indicates the number of patients who developed the irAE (n) out of the total number of patients who were either positive or negative at baseline for the indicated antibody (N).

  • CCP2, cyclic citrullinated peptides ; irAE, immune-related adverse event ; RF, rheumatoid factor; Tg, thyroglobulin ; TPO, thyroid peroxidase .